Results 101 to 110 of about 7,527 (191)

Dietary nitrate and nitrite protect against doxorubicin‐induced cardiac fibrosis and oxidative protein damage in tumor‐bearing mice

FEBS Open Bio, Volume 16, Issue 3, Page 584-594, March 2026.
Chemotherapies such as doxorubicin can have toxic effects on healthy cardiovascular/heart tissue. Following up on a doxorubicin toxicity study in mice without tumors where nitrate water was cardioprotective (lessened toxicity), this study with tumor‐bearing mice undergoing doxorubicin treatment showed no negative effect of nitrate and nitrite on drug ...
Rama D. Yammani, Xiaofei Chen, Nildris Cruz‐Diaz, Xuewei Zhu, Swati Basu, Daniel B. Kim‐Shapiro, David R. Soto‐Pantoja, Leslie B. Poole   +7 more
wiley   +1 more source

High‐Throughput In Vivo Screening Using Barcoded mRNA Identifies Lipid Nanoparticles With Extrahepatic Tropism for In Situ Immunoengineering

Advanced Materials, Volume 38, Issue 13, 3 March 2026.
A high‐throughput in vivo mRNA LNP screening platform is developed and employed to screen a large library of 122 mRNA LNPs in vivo for delivery to immune, stromal, and parenchymal cells, identifying promising LNP candidates. A novel small particle flow cytometry‐based protein adsorption analysis method is utilized to interrogate protein corona ...
Alex G. Hamilton, Ajay S. Thatte, Junchao Xu, Zhangyi Luo, Hannah C. Safford, Kelsey L. Swingle, Jenna Muscat‐Rivera, Michael Kegel, Xuexiang Han, Ryann A. Joseph, Amanda M. Murray, Hannah C. Geisler, Ricardo C. Whitaker, Lulu Xue, Roman Spektor, Jilian R. Melamed, Drew Weissman, Michael J. Mitchell   +17 more
wiley   +1 more source

Secretory Production of Plant Heme-Containing Globins by Recombinant Yeast via Precision Fermentation

Foods
Leghemoglobin (LegHb) is a plant-derived heme-containing globin found in the root nodules of legumes like soybean that can be used as a food additive for red color and meaty flavor as a plant-based meat alternative.
Ha-Neul Bae, Geun-Hyung Kim, Seung-Oh Seo   +2 more
doaj   +1 more source

Longitudinal plasma interleukin‐6 and post‐stroke cognitive outcomes: The Stroke‐IMPaCT study

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Inflammatory factors, particularly interleukin (IL)‐6, are implicated in post‐stroke cognitive decline, yet the association with longitudinal changes in these markers remains unclear. METHODS Plasma IL‐6 and other inflammatory markers were measured within 96 hours of ischemic stroke, and at 6–9 and 18–21 months, alongside ...
Natasha S. Carmichael, Harry R. Deijnen, Siew Yan Wong, Thomas O. Williams, Evangelos Kontopantelis, Luke Cowie, Eileen Jones, Lauren Drag, Marion S. Buckwalter, John R. Grainger, Stuart M. Allan, Craig J. Smith   +11 more
wiley   +1 more source

Iron, arginine, and redox metabolism in peripheral blood mononuclear cells distinguishes sickle cell disease and pulmonary hypertension

HemaSphere, Volume 10, Issue 3, March 2026.
Abstract Pulmonary hypertension (PH) is a severe vascular complication of sickle cell disease (SCD); yet, not all patients with SCD develop PH, and PH also arises independently. This duality underscores the need to understand their intersecting biology.
Francesca I. Cendali, Christina Lisk, Amy Argabright, Monika Dzieciatkowska, Nishant K. Rana, Delaney Swindle, Daniel Stephenson, Julie McAfee, Natalie Westover, Melissa Lucero, Aneta Gandjeva, Kurt Stenmark, Rubin Tuder, Brian B. Graham, Tim Lahm, Vijaya Karoor, Gemlyn George, Kathryn Hassel, Rachelle Nuss, Pavel Davizon‐Castillio, Paul W. Buehler, Angelo D'Alessandro, David C. Irwin   +22 more
wiley   +1 more source

Assessing Liver and Iron Markers in Steady State Pediatric SCD Patients to Ascertain the Hepatic Consequences of Hemotransfusion: A Case‐Control Study in Ghana

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Between 200,000 and 300,000 children with sickle cell disease (SCD) are born in Africa every year, with 75%–80% of these children living in sub‐Saharan Africa. In newborns with SCD, significant iron accumulations may develop because of their increased risk of requiring multiple blood transfusions. This study aimed to assess
John Agyemang Sah, Stephen Twumasi, Allwell Adofo Ayirebi, Benedict Sackey, Enoch Odame Anto, Richard Vikpebah Duneeh, Ebenezer Senu, Veronica Barnor, David Boakye, Daniel Nii Martey Antonio, Wina Ivy Ofori Boadu   +10 more
wiley   +1 more source

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang   +3 more
wiley   +1 more source

Society for Maternal‐Fetal Medicine Consult Series #75: Evaluation and management of non‐immune hydrops fetalis

Pregnancy, Volume 2, Issue 2, March 2026.
Abstract Non‐immune hydrops fetalis (NIHF) can result from a multitude of underlying causes, such as fetal genetic diseases, congenital anomalies, infections, fetal arrhythmias, placental tumors, monochorionic twin complications, and other disorders.
Society for Maternal‐Fetal Medicine (SMFM), Teresa. N. Sparks, Mary. E. Norton, SMFM Publications Committee   +3 more
wiley   +1 more source

Unstable Hemoglobin, a Rare but Significant Cause of Hemolytic Anemia: Recognition of Peripheral Smear Findings Is Crucial for Diagnosis

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 237-239, April 2026.
Ryan C. Shean, Archana Agarwal, Anton V. Rets   +2 more
wiley   +1 more source

Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Despite the fact that modeling and simulation are now recognized as promising innovative methodologies, their use in the context of development of drugs for sickle cell disease and Thalassemia has not yet been reviewed. Considering the challenges of conducting clinical trials for hemoglobinopathies, our work aims at exploring the current ...
Grace Shalom Govere, Jean‐Michel Dogné, Flora Musuamba   +2 more
wiley   +1 more source